Adhera Therapeutics, Inc.
ATRX
$0.0001
$0.000.00%
| Weiss Ratings | ATRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | ATRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | ATRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 10.87 | |||
| Price History | ATRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 0.00% | |||
| 60-Day Total Return | 0.00% | |||
| 90-Day Total Return | -95.83% | |||
| Year to Date Total Return | 0.00% | |||
| 1-Year Total Return | -99.17% | |||
| 2-Year Total Return | -99.98% | |||
| 3-Year Total Return | -99.99% | |||
| 5-Year Total Return | -99.98% | |||
| 52-Week High % Change | -99.41% | |||
| 52-Week Low % Change | 0.00% | |||
| Price | ATRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.02 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Sep 06, 2024 | |||
| 52-Week High Price (Date) | Jun 28, 2024 | |||
| Valuation | ATRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.16K | |||
| Enterprise Value | 10.80M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.25 | |||
| Earnings Per Share Growth | -66.51% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.00 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -8.44 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | ATRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 4.30M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ATRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 919 518 3748 | |||
| Address | 8000 Innovation Parkway Baton Rouge, LA 70820 | |||
| Website | adherathera.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | ATRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | ATRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -532.95% | |||
| Return on Equity | -- | |||
| Income Statement | ATRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -1.28M | |||
| Net Income (TTM) | -4.49M | |||
| Net Income Avl. to Common (TTM) | -4.49M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -96.06% | |||
| EPS Diluted (TTM) | -1.25 | |||
| EPS Diluted Growth (Q YOY) | -44.78% | |||
| Balance Sheet | ATRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 32.40K | |||
| Cash Per Share (Q) | $0.01 | |||
| Total Current Assets (Q) | 44.10K | |||
| Total Preferred Equity (Q) | 0.00 | |||
| Total Equity (Q) | -26.32M | |||
| Current Ratio (Q) | 0.002 | |||
| Book Value Per Share (Q) | -$5.09 | |||
| Total Assets (Q) | 44.10K | |||
| Total Current Liabilities (Q) | 26.36M | |||
| Total Debt (Q) | 10.83M | |||
| Total Liabilities (Q) | 26.36M | |||
| Total Common Equity (Q) | -26.32M | |||
| Cash Flow | ATRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 707.80K | |||
| Net Change in Cash (TTM) | -100.40K | |||
| Levered Free Cash Flow (TTM) | 564.00K | |||
| Cash from Operations (TTM) | -808.20K | |||
